August 16, 2025 — Late yesterday FDA granted Wegovy (semaglutide 2.4 mg) a big new indication – treatment of MASH. The indication FDA approved reads as follows: “For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. “The indication […]
July 1, 2025 — A dramatic race is progressing quietly and out of view for most of us. It is the race toward better therapy for the liver disease doctors know as MASH (metabolic associated steatohepatitis), which has close ties to obesity. And likewise because of advances in obesity science, progress in treating MASH is advancing with blinding speed […]
May 10, 2025 — As we are on the way to the European Congress on Obesity in Málaga, Spain, one thing stands out. The science presented at this conference will make it plain that obesity is about much more than just excess weight and weight loss.We are looking forward to an array of presentations that deal with the effects […]
May 1, 2025 — Late yesterday, the New England Journal of Medicine published interim results from a study that points to another breakthrough for semaglutide – this time for a MASH indication. The analysis includes 800 patients with MASH with an average BMI of 34.5. Only 22 patients in this trial had a BMI that indicated leanness. Nearly two […]
January 27, 2025 — A new paper this morning in Nature Medicine tells us that interrupting liver disease in obesity is possible with metabolic surgery. More specifically, in an observational study of patients with obesity and cirrhosis due to MASH, Ali Aminian and colleagues found a 72% lower risk of major complications from liver disease in patients who received […]
January 1, 2025 — Thankfully, 2024 is behind us now and we have a blank slate for a whole new year ahead of us. But what can we expect? Well, proverbial (probably Danish) wisdom tells us “prediction is difficult, especially if it’s about the future.” Nonetheless, here are our top five predictions about what we will see in 2025 […]
November 26, 2024 — For the second time this year, we have a meta-analysis of RCTs with GLP-1 medicines that affirms cardiorenal benefits in outcome studies. This latest study appears in Lancet Diabetes and Endocrinology. Lead author Sunil Badve described the importance of his analysis: “This is the first study to show a clear benefit of GLP-1 receptor agonists […]
October 30, 2024 — November is upon us and thus, so is ObesityWeek 2024 in San Antonio. This has been a year of radical change in the environment for obesity research, prevention, and care. So as we peruse the program for this meeting, it comes across as a year for consolidating the understanding of this disease and transformative options […]
July 23, 2024 — Liver disease is frighteningly common worldwide. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a buildup of fat in the liver. Formerly known as nonalcoholic fatty liver disease, this condition affects 1 in 4 people worldwide. Among those with type 2 diabetes, insulin resistance, obesity, or all three, […]
June 9, 2024 — At the EASL Congress 2024 in Milan, we witnessed quite a splash of new data on both survodutide and tirzepatide for MASH. Friday and Saturday gave us two headline presentations at the meeting and two publications in the New England Journal of Medicine. Lilly pronounced itself “very pleased” with the results of their SYNERGY-NASH study […]
